Updated on 2026/05/15

Information

 

写真a

 
FUJITA SHUNSUKE
 
Organization
Faculty of Pharmaceutical Sciences Department of Pharmaceutical Health Care and Sciences Assistant Professor
Kyushu University Hospital Pharmacy（Concurrent）
Graduate School of Pharmaceutical Sciences Department of Clinical Pharmacy（Concurrent）
School of Pharmaceutical Sciences Department of Clinical Pharmacy（Concurrent）
Title
Assistant Professor
Contact information
メールアドレス
Tel
0926426573
Profile
・臨床薬学、薬剤師養成に関する授業を担当 ・がん化学療法に伴う副作用の対応策確立に向けた研究 ・がん悪液質の対応策確立に向けた研究 ・サルコペニアの対応策確立に向けた研究
Homepage
External link

Research Areas

  • Life Science / Clinical pharmacy

Degree

  • Graduate School of Clinical Pharmacy (Kyushu University, Japan)

Research History

  •  Faculty of Pharmaceutical Sciences Department of Pharmaceutical Health Care and Sciences  Assistant Professor 

    2024.4 - Present

  • 九州大学大学院 薬学研究院 臨床育薬学分野 Assistant Professor 

    2024.4 - Present

  • 独立行政法人国立病院機構 福岡東医療センター 薬剤部 主任薬剤師 

    2023.4 - 2024.3

  • 独立行政法人国立病院機構 九州がんセンター 薬剤部 薬剤師 

    2018.4 - 2023.3

Education

  • Kyushu University   大学院薬学府   臨床薬学専攻博士後期課程

    2014.4 - 2018.3

  • Kyushu University   薬学部   臨床薬学科

    2008.4 - 2014.3

Research Interests・Research Keywords

  • Research theme： Drug repositioning research for reducing adverse effects of cancer chemotherapy

    Keyword： Cancer chemotherapy; Adverse drug reactions (ADR); Drug repositioning

    Research period： 2024 - Present

  • Research theme： Elucidating the Mechanism of Muscle Atrophy Caused by Cellular Senescence and Searching for Therapeutic Agents

    Keyword： 細胞老化、筋萎縮

    Research period： 2024 - Present

  • Research theme： Elucidating the Mechanism of Diabetic Sarcopenia and Searching for Therapeutic Agents

    Keyword： 糖尿病、サルコペニア、筋萎縮

    Research period： 2024 - Present

Papers

  • Concomitant Use of DPP-4 Inhibitors May Prevent the Development of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Cohort Study Reviewed

    Mine Keisuke, Fujita Shunsuke, Kawashiri Takehiro, Mori Yusuke, Ueda Mami, Kobayashi Daisuke, Uchida Mayako, Koura Yusuke, Hirota Takeshi, Kaneko Risa

    Clinical and Translational Science   19 ( 2 )   e70500   2026.2   （ ISSN:17528054 eISSN:17528062 ）

    　More details

    Language：English   Publisher：Wiley  

    Oxaliplatin-induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem. Previous basic studies have suggested that the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin may prevent OIPN. To evaluate whether concomitant use of DPP-4 inhibitors could prevent the development of OIPN in clinical practice, we retrospectively analyzed data from 1180 patients who initiated oxaliplatin treatment at Kyushu University Hospital between January 1, 2009 and December 31, 2019. The primary endpoint was the occurrence of OIPN of any grade. Kaplan–Meier analysis with cumulative doses demonstrated a significantly lower incidence of OIPN in the DPP-4 inhibitor group (p = 0.0422). After propensity score matching to adjust for patient backgrounds, the protective association remained significant (p = 0.0389). Furthermore, Cox proportional hazards analysis incorporating gender, age, regimen, and concomitant DPP-4 inhibitor use as covariates confirmed that DPP-4 inhibitor use was an independent protective factor for OIPN (HR = 0.690; 95% CI, 0.490–0.972; p = 0.034). These findings suggest that concomitant use of DPP-4 inhibitors may moderate the development of OIPN in patients receiving oxaliplatin.

    CiNii Research

  • Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims data. Reviewed International journal

    Takehiro Kawashiri, Naru Yamamoto, Masaki Fujiwara, Tadashi Shimizu, Daisuke Kobayashi, Shunsuke Fujita, Nobuhito Shibata, Takeshi Hirota, Mayako Uchida

    Journal of the National Cancer Institute   2026.2   （ ISSN:0027-8874 eISSN:1460-2105 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Hematologic malignancies, including leukemias and lymphomas, remain life‑threatening diseases for which preventive strategies have not yet been established. Recent studies have suggested that sodium-glucose cotransporter 2 (SGLT2) inhibitors have cancer-suppressive properties. This study investigated whether SGLT2 inhibitors are associated with reduced risk of hematologic malignancies in patients with diabetes, using a large-scale medical database. METHODS: Data of patients with diabetes prescribed diabetes medications were extracted from the JMDC Payer database (January 2005 to November 2023). After exclusions, patients were categorized into SGLT2 inhibitor (N = 158,877) and non-SGLT2 inhibitor (N = 118,678) groups. Propensity score matching, accounting for patient characteristics, resulted in 102,478 matched patients per group. The primary endpoint was time to hematologic malignancy; secondary endpoints were time to lymphoma, leukemia, and their subcategories. RESULTS: The incidence of hematologic malignancies was lower in the SGLT2 inhibitor group than in the non-SGLT2 inhibitor group (P<.001, hazard ratio (HR)=0.73[0.62-0.86], risk difference at 5 years (RD)=-0.16%). Lymphoma incidence was also lower in the SGLT2 inhibitor group (P=.003, HR = 0.71[0.57-0.89], RD=-0.12%), whereas no clear evidence of difference was observed for leukemia (P=.06, HR = 0.76[0.57-1.01], RD=-0.02%). Lymphocytic leukemia was associated with lower incidence compared to the non-SGLT2 inhibitor group (P=.04, HR = 0.44[0.19-0.99], RD=-0.02%), whereas no clear evidence of difference was observed for myeloid leukemia (P=.12, HR = 0.76[0.54-1.08], RD=-0.01%). Regarding acute myeloid leukemia (AML), the incidence was low in the SGLT2 inhibitor group (P=.001, HR = 0.34[0.19-0.62], RD=-0.05%). CONCLUSION: SGLT2 inhibitor use may be associated with lower risk of hematologic malignancies in adults with diabetes.

    DOI： 10.1093/jnci/djag038

    Web of Science

    PubMed

  • Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study Reviewed

    Yusuke Koura, Keisuke Mine, Shunsuke Fujita, Takehiro Kawashiri, Yusuke Mori, Mami Ueda, Risa Kaneko, Takeshi Hirota, Mayako Uchida, Daisuke Kobayashi

    Clinical and Translational Science   19 ( 2 )   e70500   2026.2   （ ISSN:1752-8054 eISSN:1752-8062 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Clinical and Translational Science  

    Oxaliplatin-induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem. Previous basic studies have suggested that the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin may prevent OIPN. To evaluate whether concomitant use of DPP-4 inhibitors could prevent the development of OIPN in clinical practice, we retrospectively analyzed data from 1180 patients who initiated oxaliplatin treatment at Kyushu University Hospital between January 1, 2009 and December 31, 2019. The primary endpoint was the occurrence of OIPN of any grade. Kaplan–Meier analysis with cumulative doses demonstrated a significantly lower incidence of OIPN in the DPP-4 inhibitor group (p = 0.0422). After propensity score matching to adjust for patient backgrounds, the protective association remained significant (p = 0.0389). Furthermore, Cox proportional hazards analysis incorporating gender, age, regimen, and concomitant DPP-4 inhibitor use as covariates confirmed that DPP-4 inhibitor use was an independent protective factor for OIPN (HR = 0.690; 95% CI, 0.490–0.972; p = 0.034). These findings suggest that concomitant use of DPP-4 inhibitors may moderate the development of OIPN in patients receiving oxaliplatin.

    DOI： 10.1111/cts.70500

    Web of Science

    Scopus

    PubMed

  • Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. Reviewed

    Yusuke Mori, Keisuke Mine, Takehiro Kawashiri, Yusuke Koura, Mami Ueda, Risa Kaneko, Shunsuke Fujita, Akito Tsuruta, Satoru Koyanagi, Daisuke Kobayashi

    Journal of pharmacological sciences   159 ( 4 )   279 - 282   2025.12   （ ISSN:1347-8613 eISSN:1347-8648 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Journal of Pharmacological Sciences  

    Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose-limiting toxicity with limited countermeasures. Basic research has revealed that omeprazole, a proton pump inhibitor (PPI), exerts preventive effects against OIPN. In this study, we evaluated whether other PPIs exert similar effects via in vitro and in vivo experiments. Notably, esomeprazole, lansoprazole, and rabeprazole, classified as PPIs, prevented oxaliplatin-induced cultured F11 neuronal cell damage, and repeated PPI administration prevented mechanical allodynia in rats. However, vonoprazan, a potassium ion-competitive acid blocker, did not exert such effects. Overall, our results highlight the class effects of PPIs against OIPN.

    DOI： 10.1016/j.jphs.2025.09.010

    Web of Science

    Scopus

    PubMed

  • Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity(タイトル和訳中) Reviewed

    Mori Yusuke, Mine Keisuke, Kawashiri Takehiro, Koura Yusuke, Ueda Mami, Kaneko Risa, Fujita Shunsuke, Tsuruta Akito, Koyanagi Satoru, Kobayashi Daisuke

    Journal of Pharmacological Sciences   159 ( 4 )   279 - 282   2025.12   （ ISSN:1347-8613 ）

    　More details

    Language：English   Publisher：(公社)日本薬理学会  

  • The Effect of Diabetes Medication on the Scores of the GNRI and CONUT Nutritional Indices: Cross-Sectional and Longitudinal Retrospective Studies. Reviewed International journal

    Fujita, S; Nagata, K; Kinjo, K; Mimata, H; Sonoda, T; Mine, K; Kawashiri, T; Hirota, T; Uchida, M; Kobayashi, D

    Clinical and translational science   18 ( 11 )   e70423   2025.11   （ ISSN:1752-8054 eISSN:1752-8062 ）

    　More details

    Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Clinical and Translational Science  

    Malnutrition implies a decline in the systemic status and organ function, which is closely related to sarcopenia, frailty, osteoporosis, and prognosis. Diabetes medications work in a multifaceted manner on various tissues, such as the pancreas, muscle, liver, and adipose tissue; these medications affect metabolism, which in turn affects nutritional status. This study aimed to determine the effect of diabetes medications on the scores of the Geriatric Nutrition Risk Index (GNRI) and Controlling Nutritional Status (CONUT) nutritional indices, both cross-sectionally and longitudinally. This cross-sectional study included 2146 individuals who were prescribed diabetes medications. Multivariate analysis showed that both GNRI and CONUT scores tended to be improved in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase 4 inhibitors (DPP4i), or biguanide (BG). Additionally, propensity score matching of nutrition-related laboratory values was performed to assess the variation in nutritional indices over time, which resulted in less deterioration of the GNRI in the SGLT2i and BG groups. In conclusion, this study suggests that SGLT2i and BG prevent the progression of malnutrition and may help in selecting drugs that consider the nutritional status of patients.

    DOI： 10.1111/cts.70423

    Web of Science

    Scopus

    PubMed

  • The Effect of Diabetes Medication on the Scores of the GNRI and CONUT Nutritional Indices: Cross-Sectional and Longitudinal Retrospective Studies Reviewed

    Fujita Shunsuke, Nagata Kenichiro, Kinjo Kano, Mimata Haruka, Sonoda Taiga, Mine Keisuke, Kawashiri Takehiro, Hirota Takeshi, Uchida Mayako, Kobayashi Daisuke

    Clinical and Translational Science   18 ( 11 )   2025.11   （ ISSN:17528054 eISSN:17528062 ）

    　More details

    Language：English   Publisher：Wiley  

    Malnutrition implies a decline in the systemic status and organ function, which is closely related to sarcopenia, frailty, osteoporosis, and prognosis. Diabetes medications work in a multifaceted manner on various tissues, such as the pancreas, muscle, liver, and adipose tissue; these medications affect metabolism, which in turn affects nutritional status. This study aimed to determine the effect of diabetes medications on the scores of the Geriatric Nutrition Risk Index (GNRI) and Controlling Nutritional Status (CONUT) nutritional indices, both cross-sectionally and longitudinally. This cross-sectional study included 2146 individuals who were prescribed diabetes medications. Multivariate analysis showed that both GNRI and CONUT scores tended to be improved in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase 4 inhibitors (DPP4i), or biguanide (BG). Additionally, propensity score matching of nutrition-related laboratory values was performed to assess the variation in nutritional indices over time, which resulted in less deterioration of the GNRI in the SGLT2i and BG groups. In conclusion, this study suggests that SGLT2i and BG prevent the progression of malnutrition and may help in selecting drugs that consider the nutritional status of patients.

    CiNii Research

  • Response to Comment on "Proton Pump Inhibitor Concomitant Use to Prevent Oxaliplatin-Induced Peripheral Neuropathy: Clinical Retrospective Cohort Study". Reviewed International journal

    Keisuke Mine, Takehiro Kawashiri, Yusuke Mori, Shunsuke Fujita, Mayako Uchida, Takaaki Yamada, Nobuaki Egashira, Ichiro Ieiri, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe, Daisuke Kobayashi

    Pharmacotherapy   45 ( 9 )   623 - 624   2025.8   （ ISSN:0277-0008 eISSN:1875-9114 ）

    　More details

    Language：English   Publisher：Pharmacotherapy  

    DOI： 10.1002/phar.70054

    Web of Science

    Scopus

    PubMed

  • Proton pump inhibitor concomitant use to prevent oxaliplatin-induced peripheral neuropathy: Clinical retrospective cohort study. Reviewed International journal

    Keisuke Mine, Takehiro Kawashiri, Kohei Mori, Yusuke Mori, Haruna Ishida, Hibiki Kudamatsu, Shunsuke Fujita, Mayako Uchida, Takaaki Yamada, Nobuaki Egashira, Ichiro Ieiri, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe, Daisuke Kobayashi

    Pharmacotherapy   45 ( 7 )   435 - 447   2025.5   （ ISSN:0277-0008 eISSN:1875-9114 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Pharmacotherapy  

    BACKGROUND: Oxaliplatin-induced peripheral neuropathy (OIPN) is a major clinical challenge because it leads to discontinuation of chemotherapy. Omeprazole, a proton pump inhibitor (PPI), has been shown to prevent OIPN in a rat model. Therefore, we aimed to test whether the concomitant use of a PPI reduces oxaliplatin discontinuation due to OIPN. METHODS: This retrospective study used data from 1015 patients who started treatment with oxaliplatin and evaluated two cohorts (PPI vs. non-PPI). The primary outcome measure was oxaliplatin discontinuation due to OIPN. A Kaplan-Meier curve was generated for cumulative doses and evaluated using the log-rank test and Cox proportional hazards analysis. RESULTS: The log-rank test showed that the number of patients who discontinued oxaliplatin due to OIPN was significantly lower in the PPI group (p = 0.0264). Cox proportional hazards analysis incorporated and analyzed factors previously reported as potentially affecting neuropathy (sex, age, use of PPIs, calcium channel antagonists, opioids and adjuvant analgesics, and the CAPOX [capecitabine + oxaliplatin] regimen). The analysis suggested that the concomitant use of PPIs was a factor in reducing oxaliplatin discontinuation (adjusted hazard ratio [HR] = 0.568, 95% confidence interval [CI], 0.344-0.937, p = 0.0269). Since there were significant differences in some patient demographics between the two groups, propensity score matching was performed to align the patient demographics and then reanalyzed. After propensity score matching, the same analysis as above showed that oxaliplatin discontinuation due to OIPN was significantly less common in the PPI group (p = 0.0081); cox proportional hazards analysis showed that PPI use was a factor that significantly reduced oxaliplatin discontinuation due to OIPN (adjusted HR = 0.478, 95% CI, 0.273-0.836, p = 0.0096). CONCLUSIONS: These results suggest that concomitant PPI use may reduce oxaliplatin discontinuation due to OIPN in patients receiving oxaliplatin.

    DOI： 10.1002/phar.70028

    Web of Science

    Scopus

    PubMed

  • Possible prevention of paclitaxel-induced peripheral neuropathy by concomitant use of α1-receptor antagonist based on a retrospective study. Reviewed International journal

    Kohei Mori, Takehiro Kawashiri, Keisuke Mine, Haruna Ishida, Yusuke Mori, Mami Ueda, Yusuke Koura, Shunsuke Fujita, Akito Tsuruta, Nobuaki Egashira, Ichiro Ieiri, Satoru Koyanagi, Takao Shimazoe, Daisuke Kobayashi

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   33 ( 4 )   316 - 316   2025.4   （ ISSN:0941-4355 eISSN:1433-7339 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Supportive Care in Cancer  

    PURPOSE: Paclitaxel and albumin-bound paclitaxel are important anticancer drugs for the treatment of non-small cell lung, pancreatic, gastric, and gynecological cancers; however, they cause peripheral neuropathy as an adverse reaction. Therefore, prophylaxis and treatment for peripheral neuropathy are needed, since there are no sufficient evidence-based strategies to prevent it. Our previous animal research and adverse effect database analysis studies have identified the potential of α1 antagonists to attenuate paclitaxel-induced peripheral neuropathy (PIPN). The purpose of the present study was to investigate the prophylactic potential of α1 antagonists for PIPN in patients with cancer. METHODS: Data were collected from the medical records of 673 male patients aged 18 years and older who started treatment with paclitaxel- or albumin-bound paclitaxel-containing regimens at Kyushu University Hospital between January 1, 2013, and December 31, 2019. The two primary outcome measures were PIPN occurrence and paclitaxel discontinuation due to PIPN. Kaplan-Meier curves were generated for cumulative doses and evaluated using the log-rank test. RESULTS: The percentage of patients in whom PIPN occurred (any grade) during the entire study period was 37.4% and 20.0% in without and with α1-receptor antagonist groups, respectively (P = 0.0101, χ2 test). The incidence of PIPN (any grade) was significantly lower in the α1 antagonists combination group (N = 55) than in the no α1-receptor antagonists group (N = 618) (P = 0.0425, log-rank test). However, there were no significant differences between the two groups in the discontinuation of paclitaxel due to PIPN (P = 0.9654). CONCLUSIONS: The present retrospective cohort study may suggest that concomitant use of α1-receptor antagonists may moderate the development of PIPN.

    DOI： 10.1007/s00520-025-09368-y

    Web of Science

    Scopus

    PubMed

  • 雄ラットのパクリタキセル誘発性末梢神経障害はスーパーオキシドジスムターゼ模倣薬であるカルマンガホジピルによって軽減される(Paclitaxel-induced peripheral neuropathy in male rats attenuated by calmangafodipir, a superoxide dismutase mimetic) Reviewed

    Kawashiri Takehiro, Mori Kohei, Ishida Haruna, Ueda Mami, Yao Kozo, Nagahama Fumiko, Mine Keisuke, Mori Yusuke, Koura Yusuke, Fujita Shunsuke, Shimazoe Takao, Kobayashi Daisuke

    Journal of Pharmacological Sciences   157 ( 1 )   8 - 11   2025.1   （ ISSN:1347-8613 ）

    　More details

    Language：English   Publisher：(公社)日本薬理学会  

    雄ラットモデルを用いて、スーパーオキシドジスムターゼ模倣薬であるカルマンガホジピル(CAL)が、パクリタキセル(PTX)誘発性末梢神経障害に対する予防効果について検討した。雄ラットにPTXを反復投与(6mg/kg、腹腔内投与、週1回、4週間)すると末梢神経障害(PN)が誘発され、von Frey試験における機械的異痛症と坐骨神経の軸索変性を認めた。CAL投与(1～10mg/kg、静脈内投与、週3回、4週間)では、PTX誘発性機械的異痛症と軸索変性が予防された。これらの結果から、CALはPTX誘発性PNを抑制することが示唆された。

  • Paclitaxel-induced peripheral neuropathy in male rats attenuated by calmangafodipir, a superoxide dismutase mimetic. Reviewed

    Takehiro Kawashiri, Kohei Mori, Haruna Ishida, Mami Ueda, Kozo Yao, Fumiko Nagahama, Keisuke Mine, Yusuke Mori, Yusuke Koura, Shunsuke Fujita, Takao Shimazoe, Daisuke Kobayashi

    Journal of pharmacological sciences   157 ( 1 )   8 - 11   2025.1   （ ISSN:1347-8613 eISSN:1347-8648 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Journal of Pharmacological Sciences  

    Paclitaxel induces peripheral neuropathy, which is considered a dose-limiting factor. However, appropriate prophylactic agents are currently unavailable. We investigated the prophylactic effects of calmangafodipir, a superoxide dismutase mimetic, on paclitaxel-induced peripheral neuropathy using a male rat model. Repeated administration of paclitaxel (6 mg/kg, intraperitoneal, once weekly for 4 weeks) resulted in mechanical allodynia in the von Frey test and axonal degeneration in the sciatic nerve. Conversely, calmangafodipir (1-10 mg/kg, intravenous, thrice weekly for 4 weeks) prevented mechanical allodynia and axonal degeneration induced by paclitaxel. These results suggest that calmangafodipir may inhibit paclitaxel-induced peripheral neuropathy.

    DOI： 10.1016/j.jphs.2024.11.004

    Web of Science

    Scopus

    PubMed

  • アベマシクリブ投与後の血清クレアチニン値と治療効果および副作用に関する後方視的検討 Reviewed

    大橋 邦央, 樋口 文子, 筒井 佑紀, 藤田 隼輔, 安 武夫

    日本臨床腫瘍薬学会雑誌   37   6 - 15   2024.7

    　More details

    Language：Japanese   Publisher：(一社)日本臨床腫瘍薬学会  

    アベマシクリブはクレアチニンの尿細管分泌を阻害するが、アベマシクリブ投与後に血清クレアチニン(Scr)値が投与前の1.4倍まで上昇を認めたとしても、減量や休薬の対処が必要ないとされている。本研究ではアベマシクリブが投与された乳癌患者116名を対象に投与4週目のScr上昇率で2群(1.4倍以下群、1.4倍超群)に分け患者背景、効果および副作用との関連を調査した。その結果、投与4週目のScr上昇率にアベマシクリブ投与前の腎機能の影響は認められなかった。治療効果では、無増悪生存期間中央値が1.4倍以下群463日、1.4倍超群309日で差は認めなかった。また、副作用では、投与4週目または8週目までのアベマシクリブの減量・休薬は1.4倍以下群で有意に多く、1.4倍以下群で重篤な骨髄抑制が多く認められた。骨髄抑制発生状況の違いが、両群の減量・休薬率の差に影響を及ぼした可能性が示唆された。(著者抄録)

  • Retrospective Study of the Relationship between Increased Serum Creatinine Level after Administration of Abemaciclib and Treatment Efficacy and Side Effects Reviewed

    Kunio Oohashi, Ayako Higuchi, Yuki Tsutsui, Shunsuke Fujita, Takeo Yasu

    日本臨床腫瘍薬学会雑誌   37   6 - 15   2024.7   （ eISSN:2189-129X ）

    　More details

  • Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. Reviewed International journal

    Shunsuke Fujita, Takeshi Hirota, Ryo Sakiyama, Misaki Baba, Ichiro Ieiri

    Journal of neurochemistry   2019.2

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats. Reviewed International journal

    Shunsuke Fujita, Soichiro Ushio, Nana Ozawa, Ken Masuguchi, Takehiro Kawashiri, Ryozo Oishi, Nobuaki Egashira

    PloS one   2015.11

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Oxaliplatin induces hypomyelination and reduced neuregulin 1 expression in the rat sciatic nerve. Reviewed International journal

    Kuniaki Tsutsumi, Yuji Yamashita, Soichiro Ushio, Takehiro Kawashiri, Takanori Kaname, Shunsuke Fujita, Ryozo Oishi, Nobuaki Egashira

    Neuroscience research   2014.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

▼display all

Presentations

  • オキサリプラチン使用患者におけるアレルギー発現に対するプロトンポンプ阻害薬服用の影響

    峯 圭佑, 森 裕介, 川尻 雄大, 永田 健一郎, 河良 優介, 金子 莉沙, 上田 真実, 石田 茂, 廣田 豪, 内田 まやこ, 鶴田 朗人, 小柳 悟, 藤田 隼輔, 小林 大介

    第35回日本医療薬学会年会  2025.11 

    　More details

    Event date： 2025.11

    Presentation type：Oral presentation (general)  

  • 血液腫瘍発症におけるSGLT2阻害薬処方の影響： JMDCレセプトデータを用いた大規模コホート研究

    川尻 雄大, 山元 菜留, 藤原 正規, 清水 忠, 小林 大介, 藤田 隼輔, 芝田 信人, 廣田 豪, 内田 まやこ

    第35回日本医療薬学会年会  2025.11 

    　More details

    Event date： 2025.11

    Presentation type：Poster presentation  

  • 糖尿病治療薬の残薬数を予測するモデルの構築

    國武 さくら, 川尻 雄大, 藤田 隼輔, 阿部 みどり, 浅尾 一夫, 島添 隆雄, 小林 大介

    第35回日本医療薬学会年会  2025.11 

    　More details

    Event date： 2025.11

    Presentation type：Poster presentation  

  • ペランパネルによる副作用発現と血中濃度の関連性の解析

    岩下 昂太, 藤田 隼輔, 川尻 雄大, 廣田 豪, 内田 まやこ, 小林 大介

    第35回日本医療薬学会年会  2025.11 

    　More details

    Event date： 2025.11

    Presentation type：Poster presentation  

  • オキサリプラチン誘発末梢神経障害に対するプロトンポンプ阻害薬のクラスエフェクトとしての抑制効果に関する基礎研究

    森 裕介, 峯 圭佑, 川尻 雄大, 河良 優介, 上田 真実, 金子 莉沙, 藤田 隼輔, 鶴田 朗人, 小柳 悟, 小林 大介

    第35回日本医療薬学会年会  2025.11 

    　More details

    Event date： 2025.11

    Presentation type：Poster presentation  

  • がんによる筋細胞の萎縮および抗がん薬による細胞増殖抑制効果にイメグリミンが与える影響

    藤田隼輔, 金城奏乃, 川尻雄大, 小林大介

    第145回日本薬学会第145年会  2025.3 

    　More details

    Event date： 2025.3

    Presentation type：Poster presentation  

  • パクリタキセル誘発末梢神経障害におけるTauおよびGSK-3βの関与

    石田晴多, 川尻雄大, 森皓平, 峯圭佑, 森裕介, 上田真実, 河良優介, 藤田隼輔, 小林大介

    第41回日本薬学会九州山口支部大会 

    　More details

    Event date： 2024.11

    Presentation type：Oral presentation (general)  

  • LC-MSを用いた新規抗てんかん薬の血中濃度一斉分析法の構築

    加治 侑樹, 土谷 祐一, 岩下 昂太, 金城 奏乃, 川尻 雄大, 藤田 隼輔, 峯 昌敏, 廣田 豪, 小林 大介

    第34回日本医療薬学会年会 

    　More details

    Event date： 2024.11

  • パクリタキセル誘発末梢神経障害ラットモデルにおけるcalmangafodipirの抑制効果

    川尻 雄大, 森 皓平, 石田 晴多, 上田 真実, 矢尾 幸三, 永濱 文子, 峯 圭佑, 森 裕介, 河良 優介, 藤田 隼輔, 島添 隆雄, 小林 大介

    第34回日本医療薬学会年会 

    　More details

    Event date： 2024.11

  • オキサリプラチン誘発末梢神経障害に対するDPP-4阻害薬の効果に関する調査

    藤田 隼輔、藤田 強記、清水 裕彰、山脇 一浩

    第33回 日本医療薬学会 年会  2023.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • オキサリプラチンによる神経障害ならびに抗腫瘍効果に対する 3‐Aminobenzamide の作用

    藤田 隼輔、牛尾 聡一郎、川尻 雄大、森田 春香、馬場 美咲、江頭 伸昭

    第66回 日本薬理学会 西南部会  2013.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • オキサリプラチン誘発末梢神経障害に対するエキセナチドの効果

    藤田 隼輔、牛尾 聡一郎、益口 賢、小澤 奈々、小野 佑子、馬場 美咲、川尻 雄大、 増田 智先、大石 了三、江頭 伸昭

    第87回 日本薬理学会 年会  2014.3 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • Gene Expression Analysis of Tacrolimus-Induced Tubulointerstitial Fibrosis After Ischemia/Reperfusion Injury International conference

    Shinke H, Tamura Y, Fujita S, Nakagawa S, Yano T, Matsubara K, Masuda S.

    American Society of Nephrology (Kidney Week 2014 annual meeting)  2014.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：United States  

  • オキサリプラチンの細胞内取込機構・排出機構の解明

    馬場 美咲、藤田 隼輔、崎山 良、廣田 豪、家入 一郎

    第32回 日本薬学会 九州支部大会  2015.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • 神経細胞に発現する薬物トランスポーターのオキサリプラチン取込・排出機構の解析

    崎山 良、藤田 隼輔、馬場 美咲、廣田 豪、家入 一郎

    第33回 日本薬学会 九州支部大会  2016.12 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • オキサリプラチンの神経毒性に寄与する薬物トランスポーターの解明

    藤田 隼輔、崎山 良、馬場 美咲、廣田 豪、家入 一郎

    日本薬学会 第137年会  2017.3 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • オキサリプラチンのDRG内蓄積および末梢神経障害に寄与する薬物トランスポーターの解明

    藤田 隼輔、廣田 豪、崎山 良、馬場 美咲、家入 一郎

    日本薬物動態学会 第32回 年会  2017.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • オキサリプラチン誘発末梢神経障害に対するDPP-4阻害薬の効果に関する調査

    藤田 隼輔、仲田 浩成、三角 紳博

    第29回 日本医療薬学会 年会  2019.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • 抗菌薬の選択が免疫チェックポイント阻害薬使用患者の予後に及ぼす影響

    藤田 隼輔、山下 克也

    第69回 日本化学療法学会 西日本支部総会  2021.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • オキサリプラチン誘発末梢神経障害に対するDPP-4阻害薬の効果に関する調査

    藤田 隼輔、三角 紳博

    日本医療マネジメント学会 第19回 九州・山口連合大会  2021.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • メロペネム供給停止に伴うほかの抗菌薬使用量及び緑膿菌に対する耐性菌の出現の変化について

    河野 友里、西 裕美、上田 和明、藤田 隼輔、小坂 隆介、藤野 奈緒、山脇 一浩、 肥山 和俊

    第33回 日本医療薬学会 年会  2023.11 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • オキサリプラチン誘発末梢神経障害に対するDPP-4阻害薬の効果に関する調査

    藤田 隼輔, 藤田 強記, 清水 裕彰, 山脇 一浩

    第33回 日本医療薬学会 年会  2023.11 

    　More details

    Event date： 2023.11

    Language：Japanese   Presentation type：Poster presentation  

  • メロペネム供給停止に伴うほかの抗菌薬使用量及び緑膿菌に対する耐性菌の出現の変化について

    河野 友里, 西 裕美, 上田 和明, 藤田 隼輔, 小坂 隆介, 藤野 奈緒, 山脇 一浩, 肥山 和俊

    第33回 日本医療薬学会 年会  2023.11 

    　More details

    Event date： 2023.11

    Language：Japanese   Presentation type：Poster presentation  

  • オキサリプラチン誘発末梢神経障害に対するDPP-4阻害薬の効果に関する調査

    藤田 隼輔, 三角 紳博

    日本医療マネジメント学会 第19回 九州・山口連合大会  2021.11 

    　More details

    Event date： 2021.11

    Language：Japanese   Presentation type：Oral presentation (general)  

  • 抗菌薬の選択が免疫チェックポイント阻害薬使用患者の予後に及ぼす影響

    藤田 隼輔, 山下 克也

    第69回 日本化学療法学会 西日本支部総会  2021.11 

    　More details

    Event date： 2021.11

    Language：Japanese   Presentation type：Oral presentation (general)  

  • オキサリプラチン誘発末梢神経障害に対するDPP-4阻害薬の効果に関する調査

    藤田 隼輔, 仲田 浩成, 三角 紳博

    第29回 日本医療薬学会 年会  2019.11 

    　More details

    Event date： 2019.11

    Language：Japanese   Presentation type：Poster presentation  

  • オキサリプラチンのDRG内蓄積および末梢神経障害に寄与する薬物トランスポーターの解明

    藤田 隼輔, 廣田 豪, 崎山 良, 馬場 美咲, 家入 一郎

    日本薬物動態学会 第32回 年会  2017.11 

    　More details

    Event date： 2017.11

    Language：Japanese   Presentation type：Poster presentation  

  • オキサリプラチンの神経毒性に寄与する薬物トランスポーターの解明

    藤田 隼輔, 崎山 良, 馬場 美咲, 廣田 豪, 家入 一郎

    日本薬学会 第137年会  2017.3 

    　More details

    Event date： 2017.3

    Language：Japanese   Presentation type：Poster presentation  

  • 神経細胞に発現する薬物トランスポーターのオキサリプラチン取込・排出機構の解析

    崎山 良, 藤田 隼輔, 馬場 美咲, 廣田 豪, 家入 一郎

    第33回 日本薬学会 九州支部大会  2016.12 

    　More details

    Event date： 2016.12

    Language：Japanese   Presentation type：Poster presentation  

  • オキサリプラチンの細胞内取込機構・排出機構の解明

    馬場 美咲, 藤田 隼輔, 崎山 良, 廣田 豪, 家入 一郎

    第32回 日本薬学会 九州支部大会  2015.11 

    　More details

    Event date： 2015.11

    Language：Japanese   Presentation type：Poster presentation  

  • Gene Expression Analysis of Tacrolimus-Induced Tubulointerstitial Fibrosis After Ischemia/Reperfusion Injury

    Shinke H, Tamura Y, Fujita S, Nakagawa S, Yano T, Matsubara K, Masuda S

    American Society of Nephrology (Kidney Week 2014 annual meeting)  2014.11 

    　More details

    Event date： 2014.11

    Language：English   Presentation type：Oral presentation (general)  

  • オキサリプラチン誘発末梢神経障害に対するエキセナチドの効果

    藤田 隼輔, 牛尾 聡一郎, 益口 賢, 小澤 奈々, 小野 佑子, 馬場 美咲, 川尻 雄大, 増田 智先, 大石 了三, 江頭 伸昭

    第87回 日本薬理学会 年会  2014.3 

    　More details

    Event date： 2014.3

    Language：Japanese   Presentation type：Poster presentation  

  • オキサリプラチンによる神経障害ならびに抗腫瘍効果に対する 3‐Aminobenzamide の作用

    藤田 隼輔, 牛尾 聡一郎, 川尻 雄大, 森田 春香, 馬場 美咲, 江頭 伸昭

    第 66 回 日本薬理学会 西南部会  2013.11 

    　More details

    Event date： 2013.11

    Language：Japanese   Presentation type：Poster presentation  

  • 抗菌薬の選択が免疫チェックポイント阻害薬使用患者の予後に及ぼす影響

    藤田 隼輔, 山下 克也

    日本化学療法学会雑誌  2022.3  (公社)日本化学療法学会

    　More details

    Language：Japanese  

▼display all

MISC

Professional Memberships

  • 日本医療薬学会

  • 日本薬学会

  • 日本病院薬剤師会

  • 日本臨床腫瘍薬学会

  • 日本薬学会

  • 日本臨床腫瘍薬学会

  • 日本病院薬剤師会

  • 日本医療薬学会

▼display all

Academic Activities

  • 学術論文査読

    Role(s)： Peer review

    2025

    　More details

    Type：Scientific advice/Review 

Research Projects

  • 糖尿病治療薬を活用したがん悪液質治療法の確立とがん治療に対する影響の評価

    Grant number：25K18681  2025.4 - 2027.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    藤田 隼輔

    　 More details

    Grant type：Scientific research funding

    がん悪液質は骨格筋量および筋力の低下を伴う体重減少を特徴とするがん合併症である。日常動作の制限により患者の生活の質（QOL）を低下させるだけでなく、治療効果や生命予後自体にも大きく影響することが問題とされ、予防法・治療法の確立が強く望まれている。一方、糖尿病治療薬は血糖低下を主作用とするが、複数臓器の保護作用や、ミトコンドリア機能改善、筋力維持、免疫系の調節など多面的な効果を示すことから、注目を集めている。
    本研究では、細胞および動物モデルを活用した基礎研究とがん患者を対象とした広報誌的臨床研究を実施することで、糖尿病治療薬によるがん悪液質改善作用と、がん治療に与える影響を明らかにする。

    CiNii Research

  • 抗癌剤誘発末梢神経障害の発現メカニズム解明と支持療法への展開

    Grant number：17J02826  2017 - 2018

    Japan Society for the Promotion of Science  科学研究費助成事業  Research Fellowships for Young Scientists

    　 More details

    Authorship：Principal investigator  Grant type：Joint research

Educational Activities

  • 九州大学病院薬剤部における病院実務実習の指導を担当。
    ・病院実務実習
    薬学部における病院・薬局実務実習に備えるための講義、演習および実習を担当。
    ・実務実習プレ講義
    ・実務実習プレ演習
    ・実務実習プレ実習
    薬学共用試験CBTの運営
    薬学共用試験OSCEの運営および標準模擬患者養成に関する業務

Class subject

  • 実務実習プレ実習

    2025.10 - 2026.3   Second semester

  • 実務実習プレ演習

    2025.10 - 2026.3   Second semester

  • 実務実習プレ講義

    2025.10 - 2026.3   Second semester

  • 薬学基礎実習Ⅳ

    2025.6 - 2025.8   Summer quarter

  • 薬局実務実習

    2025.4 - 2026.3   Full year

  • アドバンスト実務実習

    2025.4 - 2026.3   Full year

  • 卒業実習（アドバンスト実務実習）

    2025.4 - 2026.3   Full year

  • 病院実務実習

    2025.4 - 2026.3   Full year

  • 早期体験学習

    2025.4 - 2025.9   First semester

  • 実務実習プレ実習

    2024.10 - 2025.3   Second semester

  • 実務実習プレ講義

    2024.10 - 2025.3   Second semester

  • アドバンスト実務実習

    2024.4 - 2025.3   Full year

  • 病院実務実習

    2024.4 - 2025.3   Full year

  • 薬局実務実習

    2024.4 - 2025.3   Full year

  • 早期体験学習

    2024.4 - 2024.9   First semester

  • 基礎薬学実習IV

    2024.4 - 2024.9   First semester

  • 臨床薬学IA

    2024.4 - 2024.6   Spring quarter

  • 実務実習プレ講義

    2024.10 - 2025.3   Second semester

  • 実務実習プレ演習

    2024.10 - 2025.3   Second semester

  • 実務実習プレ実習

    2024.10 - 2025.3   Second semester

▼display all

FD Participation

  • 2024.11   Role：Participation   Title：第6回創薬産学官連携セミナー（アカデミア創薬）

    Organizer：[Undergraduate school/graduate school/graduate faculty]

  • 2024.7   Role：Participation   Title：第5回創薬産学官連携セミナー（新モダリティ）

    Organizer：[Undergraduate school/graduate school/graduate faculty]

  • 2024.4   Role：Participation   Title：令和６年度 第１回全学FD（新任教員の研修）The 1st All-University FD (training for new faculty members) in FY2024

    Organizer：University-wide

Visiting, concurrent, or part-time lecturers at other universities, institutions, etc.

  • 2025  純真学園大学院  Classification:Part-time lecturer  Domestic/International Classification:Japan 

Other educational activity and Special note

  • 2025  Special Affairs  九州大学病院薬剤部における病院実務実習の指導を担当

  • 2024  Special Affairs  九州大学病院薬剤部における病院実務実習の指導を担当

    　詳細を見る

    九州大学病院薬剤部における病院実務実習の指導を担当

Social Activities

  • 九州大学病院 薬剤部 委嘱講師.

    2024 - Present

    　More details

    2024年度, 九州大学病院 薬剤部 委嘱講師.

Activities contributing to policy formation, academic promotion, etc.

  • 2026.4 - Present   九州山口薬学会

    九州薬学会雑誌 編集委員

Notable Clinical Activities

  • 九州大学病院薬剤部における薬剤師業務・実務実習指導（令和6年度：年間145日、873時間）平成30年4月～令和6年3月　独立行政法人国立病院機構にて薬剤師として勤務